ResMed Sees FY2027 Adj EPS $12.00-$12.25 vs $12.09 Est; Sees Sales $5.750B-$5.850B vs $5.814B Est
Benzinga Newsdesk 3 weeks ago
NewsGuidance
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
ResMed (NYSE:RMD) is looking for FY2027 Adj EPS of $12.00-$12.25 vs $12.09 analyst estimate. sees sales of $5.750 billion-$5.850 billion vs $5.814 billion analyst estimate.
ResMed (NYSE:RMD) is looking for FY2027 Adj EPS of $12.00-$12.25 vs $12.09 analyst estimate. sees sales of $5.750 billion-$5.850 billion vs $5.814 billion analyst estimate.
